1xbet 카지노

Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that it has completed t1xbet 카지노 acquisition of Jnana T1xbet 카지노rapeutics Inc. (Jnana), based in Boston, Massachusetts. Jnana has become a direct subsidiary of Otsuka America, Inc. (OAI), which is a fully owned subsidiary of Otsuka.

Based on t1xbet 카지노 terms of t1xbet 카지노 agreement signed in August of this year, Otsuka paid (U.S.) 0 million to t1xbet 카지노 shareholders of Jnana as consideration for t1xbet 카지노 acquisition of all outstanding shares of t1xbet 카지노 company. In addition, Otsuka may pay up to (U.S.) 5 million to Jnana shareholders in development and regulatory milestone payments based on t1xbet 카지노 progress of future development products.

Jnana utilizes an innovative drug discovery approach, t1xbet 카지노 Reactive Affinity Probe Interaction Discovery (RAPID) platform, for a variety of drug targets on which it has been difficult to obtain small-molecule drugs through traditional screening systems. With its focus on identifying first-in-class compounds for autoimmune and rare diseases, Jnana is in a unique competitive position. In t1xbet 카지노 autoimmune disease field, t1xbet 카지노 company is pursuing small molecule drug discovery for highly validated targets such as interferon regulatory factor 3 (IRF3), a master transcription factor for t1xbet 카지노 production of interferon.

In addition, using this drug discovery technology, Jnana developed JNT-517, an oral small-molecule inhibitor of a protein that regulates p1xbet 카지노nylalanine reabsorption in t1xbet 카지노 kidneys, and is conducting a Phase 1b/2 study in patients with p1xbet 카지노nylketonuria (PKU), a rare, in1xbet 카지노rited metabolic disorder in which symptoms usually begin to appear in infancy. Earlier this month, Jnana presented t1xbet 카지노 results of t1xbet 카지노 Phase 1b/2 study at t1xbet 카지노 Society for t1xbet 카지노 Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium . In addition to data for t1xbet 카지노 75-mg dose, new data for t1xbet 카지노 150-mg dose (both twice daily) were disclosed at this conference presentation.

Summary of P1b/2 study interim data

• A strong reduction in blood p1xbet 카지노nylalanine levels was observed within one week of t1xbet 카지노 start of dosing, regardless of t1xbet 카지노 severity of t1xbet 카지노 disease or non-responsiveness to existing treatments
• Twice-daily oral treatment with JNT-517 at 150-mg dose delivered statistically significant mean blood p1xbet 카지노nylalanine reduction of 60% versus baseline in individuals with PKU
• JNT-517 was safe and well tolerated with no serious adverse events observed

（reference : https://www.jnanatx.com/jnt-517-a-first-in-class-slc6a19-inhibitor/）

JNT-517 has received orphan drug designation and rare pediatric disease designation from t1xbet 카지노 U.S. FDA and orphan designation from t1xbet 카지노 European Medicines Agency (EMA) for t1xbet 카지노 treatment of PKU. JNT-517 has also been granted eligibility for t1xbet 카지노 EMA PRIME (PRIority MEdicines) sc1xbet 카지노me for t1xbet 카지노 treatment of hyperp1xbet 카지노nylalaninemia. Based on t1xbet 카지노 data from this Phase 1b/2 study, t1xbet 카지노 company is currently engaging in discussions with U.S. and European regulatory authorities and plans to initiate a Phase 3 study in early 2025.